Resistance to activated protein C, associated with oral contraceptives use; effect of formulations, duration of assumption, and doses of oestro- progestins

Contraception

Volumn 54, Issue 3, 1996, Pages 149-152

  Olivieri, Oliviero ^b   Friso, Simonetta ^b   Manzato, Franco ^b   Grazioli, Silvia ^b   Bernardi, Francesco ^b   Lunghi, Barbara ^b   Girelli, Domenico ^b   Azzini, Margherita ^b   Brocco, Giorgio ^b   Russo, Carla ^b   Corrocher, Roberto ^a  

^a POLICLINICO BORGO ROMA   (Italy)

^b NONE

Author keywords

APC resistance; factor V; oral contraceptives; venous thrombosis

Indexed keywords

ACTIVATED PROTEIN C; CYPROTERONE ACETATE; DESOGESTREL; ESTRADIOL; ETHINYLESTRADIOL; GESTODENE;

ADULT; ARTICLE; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG FORMULATION; ENZYME REGULATION; FEMALE; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; NORMAL HUMAN; ORAL CONTRACEPTION; ORAL DRUG ADMINISTRATION; RISK ASSESSMENT; THROMBOSIS;

EID: 0030250362     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(96)00169-2     Document Type: Article

References (23)

1. 1. Jordan WM. Pulmonary embolism. Lancet 1961;2: 1146-7.
2. 2. Stadel BV. Oral contraceptives and cardiovascular disease. N Engl J Med 1981;305:612-8.
3. 3. Vessey M, Mant D, Smith A, Yeates D. Oral contraceptives and venous thromboembolism: findings in a large prospective study. BMJ 1986;292:526.
4. 4. Helmrich SP, Rosenberg L, Kaufman DW, Storm B, Shapiro S. Venous thromboembolism in relation to oral contraceptive use. Obstet Gynecol 1987;69:91-5.
5. 5. World Health Organization Collaborative Study on Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995;346:1575-82.
6. 6. Spitzer WO, Lewis MA, Heinemann LAJ, Thorogood M, Mac Rae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. BMJ 1996;312:83-7.
7. 7. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993;90:1004-8.
8. 8. Griffin JH, Evatt B, Wideman C, Fernàndez JA. Anticoagulant protein C pathway defective in majority of thrombophilia patients. Blood 1993;82:1989-93.
9. 9. Faioni EM, Franchi F, Asti D, Sacchi E, Bernardi F, Mannucci PM. Resistance to activated Protein C in nine thrombophilic families: interference in a protein S functional assay. Thromb Haemost 1993;70:1067-71.
10. 10. Koster T, Rosendaal FR, de Ronde H, Briët E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993;342:1503-6.
11. 11. Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-7.
12. 12. Voorberg J, Roelse J, Koopman R, et al. Association of idiopathic venous thromboembolism with single point-mutation at Arg 506 of factor V. Lancet 1994;343: 1535-6.
13. 13. Zöller B, Dahlbäck B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994;343:1536-8.
14. 14. Greengard JS, Eichinger S, Griffin JH, Bauer KA. Variability of thrombosis among homozygous siblings with resistance to activated protein C due to an Arg Gln mutation in the gene for factor V. N Engl J Med 1994; 331:1559-62.
15. 15. Olivieri O, Friso S, Manzato F, et al. Resistance to activated protein C in healthy women taking oral contraceptives. Br J Haematol 1995;91:465-70.
16. 16. Vasse M, Leduc O, Borg JY, Chrétien MH, Monconduit M. Resistance to activated protein C: evaluation of three functional assays. Thromb Res 1994;76:47-59.
17. 17. World Health Organization Collaborative Study on Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestins in low estrogen oral contraceptives on venous thromboembolic disease. Lancet 1995;346:1582-8.
18. 18. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Buller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation prostagen. Lancet 1995;346:1593-6.
19. 19. Jick H, Jick SS Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing prostagen components. Lancet 1995;346:1589-93.
20. 20. Böttiger LE, Boman G, Eklund G, Westerholm B. Oral contraceptives and thromboembolic disease: effect of lowering estrogen content. Lancet 1980;i:1097-101.
21. 21. Samsioe G. Coagulation and anticoagulation effects of contraceptive steroids. Am J Obstet Gynecol 1994;170: 1523-7.
22. 22. Dahlbäck B. The protein C anticoagulant system: inherited defects as basis for venous thrombosis. Thromb Res 1995;77:1-43.
23. 23. Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994;344:1453-7.